Tenecteplase differs from alteplase by having all of the following pharmacological advantages EXCEPT:

• A Greater fibrin specificity
• B Longer plasma half-life allowing single bolus administration
• C Greater resistance to plasminogen activator inhibitor-1
• D Direct activation of plasmin independent of plasminogen binding ✓

Explanation

Tenecteplase is an engineered alteplase variant with amino acid substitutions that increase fibrin specificity, prolong the half-life to allow weight-based single bolus dosing, and confer resistance to PAI-1. Like alteplase, it still acts by binding fibrin-bound plasminogen and converting it to plasmin, so option D is factually wrong. Its greater fibrin specificity means less systemic plasmin generation and fewer non-cerebral bleeding complications compared with alteplase.

Reference: Katzung Basic and Clinical Pharmacology, 15th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.